STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #310 by analyst upside · 2026-06-27
QNCX
Quince Therapeutics, Inc.
Healthcare · Market Cap $18M · P/E 0x
ANALYST PRICE TARGET
+324.0%
implied upside to consensus target
Current Price $0.94
Consensus Target $4.0
Bull Target $4.0
Bear Target $4.0
Analysts Covering 2
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
0
Hold
2
Sell
0
52-Week Low $0.79
52-Week High $45.5
YTD Return -96.9%
FUNDAMENTALS
Market Cap $18M
P/E Ratio (TTM) N/A
Forward P/E -0.7x
EPS (TTM) $-10.15
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.79
52-Week High $45.5
Current Price $0.94
Bear Target $4.0
Bull Target $4.0
● Now $0.94 ● Target $4.0
TRADING DATA
Avg Volume 4.8M
YTD Return -96.9%
Analyst Count 2
Consensus Hold
Upside to Target +324.0%
Last Updated 2026-06-27

ANALYST SUMMARY

Quince Therapeutics, Inc. (QNCX) is currently trading at $0.94 with a Wall Street consensus price target of $4.0, implying potential upside of 324.0% over the next 12 months. 2 analysts currently cover QNCX, with a consensus rating of Hold - 0% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $4.0, while the most cautious has a target of $4.0.

QNCX operates in the Healthcare sector with a market capitalisation of $18M. The stock is down 96.9% year-to-date and is currently trading near the lower end of its 52-week range of $0.79 – $45.5.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
18
out of 100
Coverage depth
8/30
Consensus clarity
8/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →